FDA posted a warning letter for PLZ Corp on June 9, 2026. For OTC drug manufacturers and private-label operators, the letter is worth reading because it turns a familiar operating assumption into a public enforcement signal: relying on supplier documentation does not remove the need to prove the result is reliable.
The pattern to watch
Supplier certificates of analysis can be useful. They are not a quality system by themselves. The question for an OTC drug manufacturer is whether incoming components, supplier qualification, specifications, review evidence, and quality-unit oversight support the decision to accept materials for use.
That is the practical read from this letter. The issue is not paperwork for its own sake. It is whether the company can show why the component record should be trusted.
Checks teams can run
- Do component specifications match the actual product and process risk?
- Are supplier COAs verified on a defined schedule?
- Does supplier qualification include evidence, not only vendor history?
- Can the quality unit show review and release decisions for accepted components?
- Would a batch record make the acceptance logic clear to someone outside the company?
FDA Warning Monitor tags this as an OTC drug-quality and supplier-quality signal because the pattern can repeat across categories: one accepted supplier record becomes the weak link in the finished-product control trail.
Source
FDA warning letter, PLZ Corp, posted June 9, 2026